Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
FDA approval
.
Show all posts
Showing posts with label
FDA approval
.
Show all posts
Tuesday, January 17, 2023
FDA Approves Sezaby (phenobarbital sodium powder for injection) for the Treatment of Neonatal Seizures
›
In continuation of my update on Phenobarbitol Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Ltd. announce...
Monday, January 16, 2023
FDA Approves Airsupra (albuterol/budesonide) Metered-Dose Inhaler to Reduce the Risk of Asthma Exacerbations
›
In continuation of my update on albuterol / budesonide Salbutamol ,/ albuterol Budesonide// Pulmicort Airsupra (albuterol/budesonide), form...
Friday, January 13, 2023
FDA Approves Sunlenca (lenacapavir) Twice-Yearly Treatment for People Living With Multi-Drug Resistant HIV
›
Gilead Sciences, Inc. (Nasdaq: GILD) announced that Sunlenca ® (lenacapavir), in combination with other antiretroviral(s) (ARV), has bee...
Wednesday, November 16, 2022
FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension
›
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) announced the U.S. Food and Drug...
Tuesday, November 15, 2022
FDA Approves Iheezo (chloroprocaine hydrochloride ophthalmic gel) for Ocular Surface Anesthesia
›
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovat...
Monday, November 14, 2022
FDA Approves Relyvrio (sodium phenylbutyrate/taurursodiol) for Patients with Amyotrophic Lateral Sclerosis (ALS)
›
In continuation of my update on phenyl butyrate and taurursodiol .. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”)...
Saturday, November 12, 2022
FDA Approves Lytgobi (futibatinib) for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
›
Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved Lytgo...
Friday, November 11, 2022
FDA Approves Furoscix (furosemide injection) for the At-Home Treatment of Congestion Due to Fluid Overload in Chronic Heart Failure
›
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential t...
Monday, October 3, 2022
FDA Approves Zoryve (roflumilast) Cream for the Treatment of Plaque Psoriasis
›
Arcutis Biotherapeutics, Inc. an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Friday, September 30, 2022
FDA Approves Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder in Adults
›
dextromethorphan Bupropion In continuation of my updates on dextromethorphan and Bupropion , Axsome Therapeutics, Inc. , a...
Thursday, September 29, 2022
FDA Approves Konvomep (omeprazole and sodium bicarbonate for oral suspension) for Gastric Ulcer and Reduction of Risk of Gastrointestinal Bleeding in Critically Ill Patients
›
In continuation of my update on omeprazole Azurity Pharmaceuticals, Inc., a pharmaceutical company focused on developing innovative do...
Monday, September 26, 2022
FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
›
Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) approval of Sotyktu ™ (deucravacitinib), a fi...
Friday, September 23, 2022
FDA Approves Terlivaz (terlipressin) for the Treatment of Hepatorenal Syndrome (HRS)
›
Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) ap...
Thursday, September 22, 2022
FDA Approves Aponvie (aprepitant) for the Prevention of Postoperative Nausea and Vomiting (PONV)
›
In continuation of my update on aprepitant Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving t...
‹
›
Home
View web version